戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 vailable on the treatment of depression with complementary therapies.
2 ial suture biology and pathology may lead to complementary therapies.
3 erventions, even the strongest proponents of complementary therapy agree that only randomized control
4 At the same time, however, the popularity of complementary therapies among prostate cancer patients c
5 non-drug treatments including behavioral and complementary therapies and lifestyle modifications.
6 support addressing patients' concerns around complementary therapy and medication adherence, preventi
7                                         Such complementary therapies are increasingly provided at mai
8 s emerged as the standard of care, and other complementary therapies are rapidly transitioning from t
9                             Conversely, most complementary therapies are well studied and of proven b
10 s try unconventional therapies and many use 'complementary' therapies, as adjuncts to mainstream care
11 nagement, nutritional practices, and related complementary therapies; assess the perceived needs of c
12 e of surgery and emerging biologic agents as complementary therapies designed to safely control infla
13  nature of cellular adaptation and calls for complementary therapies directed at the mechanisms under
14 to bright light and exercise, might serve as complementary therapies for the nonmotor manifestations
15 al studies to optimize Enbrel as a potential complementary therapy for resolution of steroid-dependen
16 s scientific data to support the efficacy of complementary therapies in the treatment of depression i
17 nding of the current evidence for or against complementary therapy in prostate cancer.
18 nd the possibilities for including effective complementary therapies into the conventional care they
19 ulosis, clinical evaluation of imatinib as a complementary therapy of tuberculosis, in particular mul
20 tion of all biofilms and as such would allow complementary therapies or disinfection procedures to be
21 ients, renders the search for alternative or complementary therapies paramount.
22 tor agents, B-cell (anti-CD20) depletion and complementary therapies represent new therapeutic horizo
23 ed eighty-eight cancer patients, referred to complementary therapy services with clinical anxiety and
24 K) cells and T cells, potentially serving as complementary therapies to immune checkpoint therapy.
25 0% and 50% of women in Western countries use complementary therapies to manage menopausal symptoms.
26        Our results point to the necessity of complementary therapies to treat the activated/inflamed
27 , 1.5%-3.8%) conditions least likely, to use complementary therapies to treat their mental condition.
28                                              Complementary therapies, willow bark and magnets, have m
29 aluated the associations of ginseng use as a complementary therapy with survival and quality of life